CIRM Funded Clinical Trials

Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects


Disease Area:
Investigator:
CIRM Grant:
CLIN2-09339-A (Closed)
Award Value:
$10,156,924.89
Investigator:
CIRM Grant:
CLIN2-09339-B (Closed)
Award Value:
$2,638,745.00
Investigator:
CIRM Grant:
CLIN2-09339-C (Active)
Award Value:
$5,827,000.00
Trial Stage:
Phase 2
Trial Status:
Completed
Targeted Enrollment:
10
ClinicalTrials.gov ID:

Details:

In ADA-SCID, allogeneic hematopoietic (blood) stem cell transplants from non-matched sibling donors are a high risk procedure. Additionally, the efficacy of chronic enzyme replacement therapy is uncertain in the long-term. A team at UCLA is using a patient’s own blood stem cells to try and rebuild the damaged immune systems of patients with ADA-SCID. They will use what’s called a lentiviral vector to deliver genetic material into the blood stem cells, correcting the genetic flaw that causes SCID. It’s hoped this will create a new blood system and a healthy immune system. Preliminary data indicates that OTL-101 – a stem cell gene therapy developed by UCLA and Orchard Therapeutics Limited – may significantly improve outcomes compared to available therapies.

Design:

Comparability of cryopreserved product versus fresh product.

Goal:

Primary: Safety. Secondary: Efficacy, gene marking, immune reconstitution. Registrational trial.

Updates:

Breakthrough Therapy Designation. Rare Pediatric Designation. Early evidence of safety and clinical efficacy in all treated patients.

News about this clinical trial:

Contact Trial Sponsor

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov